All News
Half the Experts are Wrong (2.17.2023)
Dr. Jack Cush reviews the news and tries to stump the expert panel this week on the podcast.
Read Article
Future therapies for IgG4 re dz. @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/oDgCUD0Crr https://t.co/0QSrrxmeqM
Links:
Dr. John Cush RheumNow ( View Tweet)
Case reports of anifrolumab use in 2 pts w/ chronic, scarring discoid lupus unresponsive to steriods, HCQ, immunosuppressants & CTX. Case 1 SLEDAI from 13 to 2 in 24 weeks & CLASI-A from 26 to 3 in 20wks. Cs 2 CLASI-A decr 24 to 5 after 1 infusion https://t.co/Qe2rF4Avxe
Links:
Dr. John Cush RheumNow ( View Tweet)
Implantable Vagal nerve stimulation studied in 17 active #RA pts DAS ~6. Dr Eric Ruderman #RWCS23 https://t.co/GgjdcfuVud https://t.co/EpuGgApOq5
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of HBV reactivation in HBsAg−/HBcAb+ RA ( 26 studies 2252 pts) Rx w/
b/tsDMARDs. Pooled HBV reactivation = 2%. Reactivation higher w/ RTX (esp if HBsAb−)
RTX 9% (p .03)
ABA 6%
JAKi 1%
IL‐6i 0%
TNFi 0%
Safe to use TNFi, JAKi, IL6 mAbs
https://t.co/U76or69bnB https://t.co/5QbR3WqzUG
Links:
Dr. John Cush RheumNow ( View Tweet)
Your #RA patient clearly has active disease that requires new Rx. Is your choice driven by:
Dr. John Cush RheumNow ( View Tweet)
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! Will we see you there?
https://t.co/Pv5hywp0ZQ https://t.co/lux83rqNfz
Links:
Dr. John Cush RheumNow ( View Tweet)
Does Methotrexate Increase Skin Cancer Risk?
A report from the British Journal of Cancer has also shown an increased risk of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with MTX use; and more so with higher doses.
https://t.co/8AkdkrZs44 https://t.co/ZXrqlbZiZV
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib - Effective in Systemic Lupus Erythematosus
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE.
https://t.co/YS8n02BEsk https://t.co/4sBd88AhtK
Links:
Dr. John Cush RheumNow ( View Tweet)
Can I stop MTX in RA?
Dr. Janet Pope and Dr. Charis Meng discuss ---should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis.
https://t.co/yMuVVqu0Gf https://t.co/T6PYZ6pJS4
Links:
Dr. John Cush RheumNow ( View Tweet)
Congratulations to Dr Philip Mease, the 2023 recipient of the RWCS "Kahuna" award, for lifetime excellence as a teacher/educator! @RWCSmtg #RWCS23 https://t.co/iXzQsJouu9
Dr. John Cush RheumNow ( View Tweet)
Your #RA patient clearly has active disease that requires new Rx. Is your choice driven by:
Dr. John Cush RheumNow ( View Tweet)
Future therapies for IgG4 re dz. @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/3pwBiBTf2N
Dr. John Cush RheumNow ( View Tweet)
“Pathology is helpful but not diagnostic” Dr. Dua #RWCS23 @RheumNow here are your features found on biopsy. https://t.co/J9a6S9XY2D
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Dua reviews IgG4 disease involvement at #RWCS23 @RWCSmtg @RheumNow https://t.co/WHNSxhKGUU
Dr. Rachel Tate uptoTate ( View Tweet)
Steroids assisting options - CTX, LEF or RTX @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/ENfg650B9A
Dr. John Cush RheumNow ( View Tweet)
IgG4 rel dz, steroid response is dramatic, but you need more than steroids for long term remission. @anisha_dua @RWCSmtg @RheumNow https://t.co/wq129L6DXT
Dr. John Cush RheumNow ( View Tweet)
IgG4 levels are often elevated and helpful, but not always. @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/CcdPcxYIbl
Dr. John Cush RheumNow ( View Tweet)
IgG4 rel dz pathology. @anisha_dua @RWCSmtg @RheumNow https://t.co/LKIZ1BOejK
Dr. John Cush RheumNow ( View Tweet)
IgG4 related disease (a proliferative, fibrotic dz) manifestations by Dr Aisha Dua at RWCS @anisha_dua #rwcs23 @RWCSmtg @RheumNow https://t.co/hy6ZuOY2Ti
Dr. John Cush RheumNow ( View Tweet)